Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Equity Income (2022 - 2024)

Crinetics Pharmaceuticals has reported Equity Income over the past 3 years, most recently at -$470000.0 for Q1 2024.

  • For Q1 2024, Equity Income changed N/A year-over-year to -$470000.0; the TTM value through Dec 2024 reached -$470000.0, up 90.96%, while the annual FY2024 figure was -$470000.0, 90.96% up from the prior year.
  • Equity Income for Q1 2024 was -$470000.0 at Crinetics Pharmaceuticals, up from -$4.2 million in the prior quarter.
  • Over five years, Equity Income peaked at -$470000.0 in Q1 2024 and troughed at -$4.2 million in Q4 2023.
  • A 3-year average of -$1.7 million and a median of -$1.0 million in 2022 define the central range for Equity Income.